



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref.: ADL/SE/2017-18
Date: 14th November, 2017

To,
Department of Corporate Service,
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE CODE - 524348

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 14th November, 2017.

This is for your kind information and records. Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

V. S. Ranade

Vibhav S. Ranade
Company Secretary & Compliance Officer



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press Release for September, 2017

GST transition affected sales in the beginning of Sep'17 quarter due to lack of readiness across the entire value chain in the industry. However, there was good demand towards the end of Sep'17 quarter which recovered some of the lost sales.

Consolidated EBITDA for the quarter ended Sep'17 is 52.62 crores, up by 2.9% and Consolidated Profit after tax for the quarter ended Sep'17 is 23.60 crores, up by 8.5% due to lower interest costs. Operating margins were good due to better realization in formulation division. Due to slight increase in working capital, Debt/Equity ratio was 1.19 as of Sep'17, which should reduce in coming quarter.

Company will be inviting USFDA for re-inspection in current quarter. European approvals for its APIs as well as Finished products will drive the growth in export markets. Company has got consent to operate its new intermediate facility and centralized multiple effect evaporator systems, which will enhance profit margins due to backward integration and reduce the effluent streams, thus positively contributing towards the cleaner environment.

For Aarti Drugs Limited

Adhish P. Patil
Chief Financial Officer

